Human Growth Hormone vs Mod-GRF (1-29).

Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland. The pharmaceutical form used in medicine and research is recombinant human growth hormone (rhGH, generic name somatropin), an identical 22 kDa sequence manufactured in E. coli or mammalian cells. It is one of the most studied protein hormones, marketed under brands such as Genotropin, Norditropin, Humatrope, Saizen, Nutropin, and Omnitrope.

Mod GRF 1-29 (commonly sold as "CJC-1295 without DAC") is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It is the same tetra-substituted GHRH(1-29) peptide backbone used in CJC-1295, but it lacks the maleimido "Drug Affinity Complex" (DAC) linker that the long-acting form carries, so it behaves as a short-acting GHRH secretagogue. Its parent fragment, native GHRH(1-29) ("sermorelin"), retains essentially the full GH-releasing activity of the 44-residue hormone, and the four engineered substitutions are added to slow enzymatic breakdown.

GH binds a single GH receptor (GHR) that dimerizes and signals through the JAK2/STAT5 pathway, driving transcription of target genes including IGF-1. Much of GH's anabolic and growth-promoting action is mediated indirectly by hepatic and local insulin-like growth factor 1 (IGF-1), while GH itself exerts direct effects that are often metabolically opposite to insulin: it stimulates lipolysis, promotes protein accretion, and induces a state of insulin resistance that raises blood glucose. Endogenous secretion is pulsatile, stimulated by hypothalamic GHRH and ghrelin and suppressed by somatostatin, with negative feedback from IGF-1 and GH itself. The net physiologic effects include longitudinal bone growth at open epiphyses, increased lean body mass, reduced fat mass, and altered glucose and lipid handling.

Like endogenous GHRH, the peptide binds the GHRH receptor on anterior-pituitary somatotrophs, raising intracellular cAMP and triggering pulsatile synthesis and release of growth hormone, which in turn drives hepatic IGF-1 production. The four amino-acid substitutions relative to native GHRH(1-29), typically described as D-Ala at position 2, Gln8, Ala15, and Leu27, are intended to resist degradation, with the D-alanine substitution at position 2 specifically blocking cleavage by dipeptidyl peptidase-IV (DPP-IV), the main enzyme that rapidly inactivates GHRH. Because it has no albumin-binding DAC tether, it is cleared quickly and is described as producing brief, pulse-like GH stimulation rather than the sustained "GH bleed" seen with the DAC version. It is mechanistically a secretagogue: it prompts the pituitary's own GH, rather than supplying GH directly.

The strongest human evidence is for replacement in diagnosed GH deficiency: recombinant somatropin is FDA-approved and supported by randomized trials and systematic reviews (e.g., Health Technology Assessment 2010, PMID 20849734, for pediatric growth disorders) showing improved growth velocity and adult height in children and improved body composition and quality of life in adult GHD (reviewed in Pituitary 2006, PMID 17077947). More recently, a long-acting analog, once-weekly somapacitan, was effective and well tolerated versus placebo and daily GH in adult GHD in a randomized phase 3 trial (J Clin Endocrinol Metab 2020, PMID 32022863). By contrast, evidence for GH in healthy older adults is weak and unfavorable: the landmark Rudman study (N Engl J Med 1990, PMID 2355952) reported body-composition changes in men over 60 but was small and uncontrolled for clinical endpoints, and a systematic review (Liu et al., Ann Intern Med 2007, PMID 17227934) concluded GH produces only small body-composition changes in the healthy elderly while increasing adverse events, and cannot be recommended as anti-aging therapy. Claims of fat loss, muscle gain, or longevity in healthy or athletic populations are not supported by robust controlled human outcome data.

The well-known human trials in this family, Teichman et al. (JCEM, 2006), Ionescu & Frohman (JCEM, 2006), and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), all studied CJC-1295 WITH DAC, the long-acting albumin-binding version, not the no-DAC Mod GRF 1-29; Alba et al. (2006) used a GHRH-knockout mouse model. There is no robust, peer-reviewed human clinical trial of Mod GRF 1-29 (the no-DAC peptide) under that name establishing efficacy or safety, so claims about it are largely inferred from GHRH/sermorelin pharmacology and from the DAC-form data rather than directly tested. The unmodified parent peptide, sermorelin/GHRH(1-29), was an FDA-approved diagnostic and pediatric GH agent and is the best-characterized human reference point. Most published mentions of the no-DAC compound itself come from anti-doping analytical chemistry (e.g., Henninge et al., Drug Test Anal, 2010, identifying CJC-1295 in an illicit preparation), which characterize the molecule but not its clinical effects. Honest bottom line: the human-versus-preclinical gap is wide here, and the short-acting form is plausible by analogy but essentially unproven in controlled human studies.

Documented adverse effects, drawn largely from the healthy-elderly trials and GHD populations, include fluid retention and edema, arthralgias and joint swelling, carpal tunnel syndrome, and impaired glucose tolerance or new-onset diabetes due to GH-induced insulin resistance (Liu 2007, PMID 17227934). Acromegaly-like features and gigantism follow chronic GH excess. Long-term safety signals exist: the French SAGhE analysis and related cohorts raised concern about excess circulatory/cerebrovascular mortality after childhood GH treatment, prompting an FDA safety review, though the larger pooled SAGhE cohort (Lancet Diabetes Endocrinol 2020) provided more reassuring overall mortality data; the question of long-term cardiovascular and neoplastic risk remains incompletely resolved. GH is contraindicated in active malignancy, acute critical illness, and proliferative diabetic retinopathy. Non-prescription "GH" products and gray-market vials carry additional risks of misidentification, contamination, and incorrect labeling that are not characterized in any controlled study.

Documented safety data specific to Mod GRF 1-29 are minimal because controlled human trials of the no-DAC peptide are lacking; what is known is extrapolated from GHRH analogs broadly. In studies of related GHRH analogs and sermorelin, injection-site reactions (redness, swelling), flushing, and headache are the most commonly reported effects, and any sustained elevation of the GH/IGF-1 axis carries theoretical concerns including fluid retention, joint discomfort, insulin resistance/altered glucose handling, and uncertainty about long-term proliferative risk because IGF-1 is mitogenic. A major real-world hazard is that material sold under this name is research-grade and unregulated, so purity, identity, sterility, and contamination are not assured; anti-doping case reports document the compound appearing in mislabeled or "unknown" pharmaceutical preparations. Interactions with somatostatin tone, other secretagogues, and underlying endocrine or oncologic conditions are not well characterized, and long-term human safety is simply unknown.

Recombinant somatropin is FDA-approved (first approved 1985–1987) for specific indications including pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature, idiopathic short stature, chronic renal insufficiency, adult GH deficiency, and HIV-associated wasting; non-approved uses such as anti-aging, bodybuilding, or athletic enhancement are off-label and, in the US, distribution for such uses is specifically restricted by law. GH is a prohibited substance in and out of competition under the World Anti-Doping Agency (WADA) code.

Mod GRF 1-29 / CJC-1295 without DAC is not approved by the FDA or any major regulator for any indication and is an investigational/research-use-only compound; its unmodified parent, sermorelin, was previously FDA-approved but has been commercially discontinued. As a GHRH analog it falls under the World Anti-Doping Agency (WADA) Prohibited List class S2 (peptide hormones / growth factors and related substances) and is banned in sport at all times.